Related Experiment Videos
Ligand-targeted liposomes directed against pathological vasculature
Raymond M Schiffelers1, Grietje Molema, Timo L M ten Hagen
1Dept of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, TB Utrecht, 3508, The Netherlands.
Journal of Liposome Research
|February 27, 2003
Summary
Targeted liposomes can deliver drugs to angiogenic endothelial cells, crucial for treating cancer and inflammation. This study focuses on liposomes targeting the alpha v beta 3-integrin protein for precise drug delivery.
Area of Science:
- Oncology
- Nanomedicine
- Biotechnology
Background:
- Angiogenic endothelial cells are key targets for cancer and inflammation therapies.
- Over-expressed proteins on these cells offer opportunities for site-specific drug delivery.
- Alpha v beta 3-integrin is a promising target on angiogenic endothelial cells.
Purpose of the Study:
- To design and develop long-circulating liposomes targeted to angiogenic endothelial cells.
- To investigate the potential of alpha v beta 3-integrin as a target for liposome-based drug delivery.
- To explore novel therapeutic strategies for cancer and inflammatory diseases.
Main Methods:
- Design of targeted long-circulating liposomes.
- Utilizing alpha v beta 3-integrin as the specific target molecule.
- Focus on site-specific drug delivery to angiogenic endothelial cells.
Main Results:
- Development of liposomes with potential for targeted delivery.
- Demonstration of alpha v beta 3-integrin as a viable target for liposome-based interventions.
- Prospects for enhanced therapeutic efficacy in cancer and inflammation.
Conclusions:
- Targeted liposomes offer a promising approach for cancer and inflammation treatment.
- Alpha v beta 3-integrin targeted liposomes represent a significant advancement in drug delivery.
- Further research into these targeted liposomes could lead to improved patient outcomes.